Telix Pharmaceuticals develops and commercializes radiopharmaceuticals for cancer imaging and therapy (theranostics). Its lead approved products include Illuccix, a PSMA-targeted imaging agent used in prostate cancer diagnosis and staging. The pipeline targets urologic, neuro-oncology, and other solid tumors, supported by a growing global manufacturing and distribution network for radioactive doses.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 108.9 | — | -104.1 | — |
| 2023 | 333 | 205.7% | 4.2 | — |
| 2024 | 516.5 | 55.1% | 33.7 | 700.5% |
| 2025 | 803.8 | 55.6% | -7.1 | -121.2% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Interparfums, Inc. (IPAR), Amylyx Pharmaceuticals, Inc. (AMLX), WillScot Holdings Corporation (WSC), Newmark Group, Inc. (NMRK), AbCellera Biologics Inc. (ABCL), Iovance Biotherapeutics, Inc. (IOVA)